The Israeli company Lumenis, a world leader in the development of laser for medical treatments, significantly improves the treatment of kidney stones and enlarged prostate using Mozes 2.0 technology that shortens the time of surgery and hospitalization, and improves the quality of life of patients.
The field of laser technology in the medical service is constantly evolving and has become particularly effective, especially in the field of urology treatments. The “Moses 2.0” laser technology – an Israeli development registered as a patent – significantly increases the effectiveness of laser treatments in the treatment of problems caused by kidney stones or an enlarged prostate – two common medical conditions.
Mozes 2.0 is an innovative holmium laser technology, which was developed in Lumenis’ research and development laboratories in Yokneam. Technology is turning urological treatments that were previously considered complex that require hospitalization and rehabilitation, sometimes prolonged, into treatments with better clinical outcomes during surgery, which reduce the need for a hospital stay.
The world’s leading treatment for crushing kidney stones
About 10% of the Israeli public will experience during their lifetime an attack of ‘kidney spasm’, caused by urinary tract stones, most of them men in a ratio of 1: 3 compared to women, who are in the third to fifth decade of life.
The use of a holmium-type laser in Moses 2.0 technology has become the leading treatment for crushing urinary stones and the ultimate solution to this common problem. The technology uses a unique mechanism, which divides the transmission of laser energy towards the stone and tissue into two beats. The first, creates an air pocket (bubble) in the liquid treatment space, while the second pulse transfers the rest of the holmium energy directly to the target optimally.
“The endoscopic field of urology is improving and the feeling is that the sky has been broken,” says Prof. Mordechai Duvdevani, deputy director of the urology department and director of the endo-urology unit at Hadassah Ein Kerem Hospital and secretary of the Israeli Urologists Association. “Until 30 years ago, treatment included ‘open’ surgeries, followed by extracorporeal stone crushing and then endoscopic surgeries, while large stones, over 2 cm, were treated through the waist. The new technology makes it possible to increase the range and handle larger stones, in a shorter time, and allows for a good recovery. “Even if surgery is still needed through the waist, the opening that is made is much smaller, up to 5 times more than before, which allows patients to be released after only one night.”
Moses 2.0 gives attending physicians significant clinical benefits by increasing the stone’s disintegration rate by 85 percent compared to previous laser treatments, preventing the stone from “escaping” during treatment and reducing the risk of the stone reaching distant places in the kidney and causing complications. This significantly improves the physician’s ability to control during surgery, resulting in faster, more effective and efficient treatment.
“The means of crushing have advanced greatly in recent decades, and today the standard is a helium laser – a flexible laser fiber 1/5 mm in diameter,” explains Dr. Ehud Gensin, a senior physician in the urology department at Shamir Assaf Medical Center and a senior physician at Assuta in Ramat Hachayal. ” Using the fiber and a tiny camera, you can walk on the kidney, get to the stone and smash it. The first shock wave created by the laser shot ‘smuggles’ the stone, and Lumenis engineers were able to add another shock wave in Moses 2.0 in less than a second mile, so that the stone would not move. In this way, they were able to significantly streamline the procedure, and it has become faster and more efficient than it has been to date. ‘
The future is already here: removing an enlarged prostate without hospitalization
Even in the treatment of an enlarged prostate problem in men, Mozes 2.0 technology has proven to be the most durable clinical treatment, and with minimal risk compared to other treatments on the market. In the treatment of the common disease among 50% of men over the age of 60 and about 80% of men over the age of 80, the Mozes 2.0 technology has changed the treatment practice that has been practiced for decades.
“The prostate is a gland that is at the origin of the bladder, and it grows naturally over time, until it embraces the urethra and causes men to have urinary incontinence,” explains Dr. Gensin. Naturally during their lives. ‘
According to Dr. Gensin, the most common surgery in Israel today for prostate treatment is the TURP procedure, during which a camera is inserted through the urethra, and the prostate is treated with an electric knife. TURP surgery lasts up to an hour, and is limited to treating prostates up to 80-100 cc only. It increases the chances of bleeding and especially there is a significant chance of reoperation because there is more chance of glandular tissue remaining after surgery. In addition, in the standard method it is also accompanied by a 6% chance of erectile dysfunction.
In contrast, the most advanced surgery currently offered for an enlarged prostate problem is the HoLEP procedure – Holmium Laser Enucleation of the Prostate using Moses 2.0 technology. The innovative technology shortens the operation time by more than 20% and significantly reduces the risk of bleeding. It can be performed as a day procedure and without a catheter thus shortening the hospitalization time, which usually lasts several days, so that some patients are discharged home on the same day or after only one day. The surgery can be performed under blood thinning treatment due to the excellent bleeding control ability.
“The HoLEP procedure is done through the urethra and without an incision, during which the blocking part of the prostate is fully peeled off with a holmium laser,” explains Dr. Gensin. This is without opening the abdomen, even in cases of a very large prostate. It greatly shortens the time of hospitalization and connection to the catheter, when the chance of erectile dysfunction is nil. ‘
“Lumenis’ technology developers have responded to the challenge with precision, making a change in the nature of the laser shock wave in the HoLEP process in Moses 2.0, allowing for more effective tissue peeling, more effective bleeding control, and a faster surgical procedure.”
The Israeli company Lumenis is one of the pioneers of laser surgery in the world. It is headed by CEO Tzipi Ozer-Armon, who is recording another business achievement after in March this year, Boston Scientific acquired the surgical division for $ 1.07 billion, announcing that it intends to keep the company operating in Israel and make it an innovation center in laser technologies.
“The greatest pride behind all this is an Israeli company,” concludes Prof. Duvdevani. “We are proud of the fact that a company in Israel is at the forefront of global technology. And we are happy that breakthrough technologies in the field of urology have come out of here. ”